JHS Secures Multi-Million Dollar Contracts to Manufacture Sterile Parenteral Products
News Feb 23, 2012
Jubilant HollisterStier has announced that its Contract Manufacturing & Services division has recently secured contracts with four innovator life science companies for the commercial manufacturing of sterile parenteral products for sale in the United States and Europe.
These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications.
The total value of these contracts is over US $ 90 million to be delivered over a 5 year period. Commercial transfer to the Jubilant HollisterStier manufacturing facility has commenced for all contracts.
“We have successfully helped provide safe and effective products to innovator Pharmaceutical and Biotechnology companies over the years and are committed to do so for these products as well. We are pleased to offer our support in the development and manufacture of highly complex products through the application of leading scientific solutions and utmost dedication to quality and customer service. This expansion of our globally leading parenteral manufacturing capabilities is a further outcome of our strategy to extend our offering across products and geographies.” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier.
Commenting on the multi-million dollar award, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said, “We are pleased with signing of these long term contracts with innovator pharma companies to serve the regulated markets of US and Europe and is a direct result of our increased business development efforts leading to higher utilization of our existing capacity. Jubilant is one of the leading manufacturers of sterile both liquid and lyophilized products in North America.”
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE